<DOC>
	<DOCNO>NCT00552097</DOCNO>
	<brief_summary>The purpose study determine whether ezetimibe plus simvastatin effective simvastatin alone prevent progression atherosclerosis inner layer carotid artery .</brief_summary>
	<brief_title>Effect Ezetimibe Plus Simvastatin Versus Simvastatin Alone Atherosclerosis Carotid Artery ( ENHANCE ) ( P02578 )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Genotypeconfirmed heterozygous familial hypercholesterolemia write documentation genetic diagnosis time screen LDLC &gt; =210 mg/dL ( 5.43 mmol/L ) , clinical diagnosis heterozygous familial hypercholesterolemia , define LDLC &gt; =210 mg/dL ( 5.43 mmol/L ) least one following : tendinous xanthoma child &lt; 18 year age hypercholesterolemia ( LDLC &gt; 159 mg/dL ( 4.11 mmol/L ) sibling hypercholesterolemia ( LDLC &gt; 190 mg/dL [ 4.91 mmol/L ] ) tendinous xanthoma family history LDLC value distribution pattern compatible dominant autosomal transmission least one relative present fast total cholesterol value &gt; 348 mg/dL ( 9.0 mmol/L ) exclusion secondary cause dyslipidemia LDLC &gt; =210 mg/dL ( 5.43 mmol/L ) 1 week randomization plasma triglyceride level &lt; =400 mg/dL ( 4.52 mmol/L ) pregnancy situation , condition , illness , opinion investigator , may interfere optimal participation study presence apolipoprotein B gene mutation confirm absence LDL receptor mutation either allele undergoing LDLapheresis plasma apheresis unsuitable plaque artery morphology use certain drug , food , agent know alter cholesterol level cause pharmacokinetic interaction either ezetimibe simvastatin</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>